BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 18, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ARRY-380: Interim Phase I data

Interim data from 17 evaluable patients with HER2-positive metastatic breast cancer from a dose-escalation Phase I trial showed that >=200 mg twice-daily ARRY-380 produced 1 partial response and 13 cases of stable disease, including 5...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >